Set for February in Miami Beach, the new Symposium continues the 25-year legacy of LL&M Congress and introduces first major hematology event of 2025.

MALVERN Pa., (January 8, 2025) — Nine faculty experts from the Moffitt Cancer Center in Tampa and the Sylvester Comprehensive Cancer Center at the University of Miami Health System will be featured in the inaugural Lymphoma, Leukemia & Myeloma (LL&M) Winter Symposium, highlighting and interpreting the latest clinical trial data, updates on drug approvals, and advance treatment strategies to improve care and outcomes for patients with blood cancers.

As the first major hematology meeting of 2025, to be held February 7-9 at the Fontainebleau Miami Beach Hotel, LL&M Winter Symposium will foster a vibrant exchange of ideas and practical insights of how evolving scientific evidence will impact clinical practice. Building on the 25-year legacy of the annual LL&M Congress, the LL&M Winter Symposium’s educational program will translate into practice the latest research and updates from hematology/oncology conferences around the globe, including the recent American Society of Hematology (ASH) meeting.

“The field of hematology continues to expand into a molecular era integrating targeted and immune therapies impacting patients’ daily management,” said Rami Komrokji, MD, faculty presenter and Vice Chair of the Malignant Hematology Department and senior member of the Malignant Hematology and Experimental Therapeutics Program at the Moffitt Cancer Center. “The LL&M Winter Symposium allows clinicians to hear the latest in hematology research summarized by the field experts to be implemented into their practice, which translates in my opinion into better patient care and outcomes.”

Additional faculty experts from Tampa and Miami include:

-    Melissa Alsina, MD, professor of medicine in the Blood and Marrow Transplant Program at Moffitt Cancer Center in Tampa and head of the Multiple Myeloma Transplant Program. 
-    Benjamin Diamond, MD, assistant professor at the University of Miami and member of the Myeloma Genomics Laboratory at Sylvester Comprehensive Cancer Center. 
-    C. Ola Landgren, MD, PhD, professor of medicine, Chief of the Myeloma Division, Director of Sylvester Myeloma Institute, Paul J. DiMare Endowed Chair in Immunotherapy, leader of the Experimental Therapeutics Program, and co-leader of the Translational and Clinical Oncology (TCO) program at the Sylvester Comprehensive Cancer Center, University of Miami.
-    Izidore Lossos, MD, professor of medicine, Chief of the Lymphoma Section, and Director of the Lymphoma Program at Sylvester Comprehensive Cancer Center, University of Miami, where he holds an endowed chair.
-    Craig Moskowitz, MD, Physician-in-Chief, Oncology Service Line at the Sylvester Cancer Center and professor of medicine at the Miller School of Medicine, University of Miami Health System.
-    Mikkael Sekeres, MD, MS, professor of medicine with tenure and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine. 
-    Kenneth Shain, MD, PhD, associate member at Moffitt Cancer Center, Co-Director of the Pentecost Myeloma Research Center, Scientific Director of the Moffitt Myeloma Working Group, and Director of the ORIEN Multiple Myeloma Disease Interest Group.
-    Sangeetha Veungopal, MD, MS, assistant professor in the Division of Hematology at the Sylvester Comprehensive Cancer Center at the University of Miami.

“The research on hematologic malignancies is constantly evolving,” said Morton Coleman, MD, Symposium Chair. “There is a constant flow of data, into new drug approvals and new drug uses. These clinical trial data are presented at major oncology and hematologic oncology meetings across the world. It was essential for us to create an early year symposium to talk about the trial data and make clinicians aware of what’s occurring and what it means for their practice in 2025, so they can provide optimal care for patients.”

The meeting is designed for hematologists; hematologic, medical, radiation, and surgical oncologists; hematopathologists; and allied clinicians, including pathologists, oncology and health-system pharmacists, oncology nurses, NPs, PAs, residents/fellows, and other healthcare professionals involved and/or interested in the therapeutic management of hematologic malignancies.

For more information, visit llmwintersymposium.com.   

 

ABOUT HMP GLOBAL   

HMP Global is the omnichannel market leader in healthcare events, education, and insight — with a mission to improve patient care. For 40 years, the company has built trusted brands including Psych Congress, the premier source for mental health education, and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP Global partners with leading experts around the world to deliver more than 450 annual events, medical strategy, and marketing for pharmaceutical and medical device customers through HMP Collective, and pharmaceutical market insight, engaging a global community of healthcare stakeholders that includes nearly 2 million clinicians across 600 medical specialties as well as managed care, behavioral health, senior living, emergency medical, and pharmaceutical commercialization professionals. For more information, follow HMP Global on LinkedIn or visit hmpglobal.com.